The meningococcal C conjugate vaccine (MenCC) is an interesting model with which to test the efficacy of the Monocyte Activation Test (MAT) as an alternative method of pyrogen testing in the quality control of vaccines. The MenCC that has been produced by Bio-Manguinhos in Brazil is in the final development stage, and, as recommended in the guidelines for MenCC production, its pyrogen content must be determined by using the Limulus Amoebocyte Lysate (LAL) assay and the Rabbit Pyrogen Test (RPT). This represents an ideal opportunity to compare LAL and RPT data with data obtained by using a MAT system with cryopreserved whole blood and IL-6/IL-1β as marker readouts. In order to assess the compatibility of the MAT with MenCC, endotoxin and non-endotoxin pyrogen content was quantified by using MenCC samples spiked with lipopolysaccharide (LPS), lipoteichoic acid or zymosan standards. The presence of the aluminium-based adjuvant interfered with the MAT, increasing the readout of IL-1β in LPS-spiked MenCC batches. This infringed the product-specific validation criteria of the test, and led to IL-6 being chosen as the more suitable marker readout. No pyrogenic contaminants were identified in the MenCC batches tested, demonstrating consistency among the different systems (MAT, RPT and the LAL assay). In conclusion, the introduction of the MAT during MenCC development could contribute to the elimination of animal tests post-licensing, ensuring human protection based on an effective non-animal based method of quality control.
RosensteinN.E., PerkinsB.A., StephensD.S., PopovicT., & HughesJ.M. (2001). Meningococcal disease. New England Journal of Medicine344, 1378–1388.
2.
PicciniJ.P., HellkampA.S., WashamJ.B., BeckerR.C., BreithardtG., BerkowitzS.D., HalperinJ.L., HankeyG.J., HackeW., MahaffeyK.W., NesselC.C., SingerD.E., FoxK.A., & PatelM.R. (2016). Polypharmacy and the efficacy and safety of rivaroxaban versus warfarin in the prevention of stroke in patients with nonvalvular atrial fibrillation. Circulation133, 352–360.
3.
BorrowR., AlarcónP., CarlosJ., CaugantD.A., ChristensenH., DebbagR., De WalsP., Echániz-AvilesG., FindlowJ., HeadC., HoltD., KamiyaH., SahaS.K., SidorenkoS., TahaM.K., TrotterC., Vázquez MorenoJ.A., von GottbergA., & SáfadiM.A.; Global Meningococcal Initiative (2017). The Global Meningococcal Initiative: Global epidemiology, the impact of vaccines on meningococcal disease and the importance of herd protection. Expert Review of Vaccines16, 313–328.
AndradeA.L., MinamisavaR., TomichL.M., LemosA.P., GorlaM.C., BrandileoneM.C.C., DominguesC.M.S., MoraesC., PolicenaG., & BierrenbachA.L.; Meningococcal Study Group (2017). Impact of meningococcal C conjugate vaccination four years after introduction of routine childhood immunization in Brazil. Vaccine35, 2025–2033.
6.
MoraesJ.C., KempB., de LemosA.P.S., GorlaM.C.O., MarquesE.G.L., FerreiraM.C., SacchiC., CarvalhanasT.R.M.P., RibeiroA.F., FerreiraC.M., SalgadoM.M., FukasawaL., GonçalvesM.G., HigaF., AngeramiR., FreitasA.R., SatoH.K., & SáfadiM.A.P. (2015). Prevalence, risk factors and molecular characteristics of meningococcal carriage among Brazilian adolescents. Pediatric Infectious Disease Journal34, 1197–1202.
7.
MoraesC., MoraesJ.C., SilvaG.D.M., & DuarteE.C. (2017). Evaluation of the impact of serogroup C meningococcal disease vaccination program in Brazil and its regions: A population-based study, 2001–2013. Memórias do Instituto Oswaldo Cruz112, 237–246.
SilveiraI.A., BastosR.C., NetoM.S., LaranjeiraA.P., AssisE.F., FernandesS.A., LealM.L., SilvaW.C., LeeC.H., FraschC.E., PeraltaJ.M., & JessourounE. (2007). Characterization and immunogenicity of meningococcal group C conjugate vaccine prepared using hydrazide-activated tetanus toxoid. Vaccine25, 7261–7270.
10.
JessourounE., SilveiraI.A.F.L., BastosR.C, FraschC.E., & LeeC-H.R. (2015). Process for Preparing Polysaccharide–Protein Conjugate Vaccines, United States Patent. US 9,173,931 B2.
11.
BastosR.C., de SouzaI.M., da SilvaM.N., SilvaF.P., FigueiraE.S., LealM.L., JessourounE., da SilvaJ.G.Jr., MedronhoR.A., & SilveiraI.A. (2015). Brazilian meningococcal C conjugate vaccine: Scaling up studies. Vaccine33, 4281–4287.
12.
MartinsR.M., BarbosaG.G., MaiaM.L.S., EngstromE., CamachoL.A.B., PérisséA.R., SilveiraI.A.F.B., LealM.L., MarcovistzR., HommaA., & JessourounE. (2010). Phase I study of a meningococcal C strain 2135 conjugate vaccine, p. 169. Proceedings of the 17th International Pathogenic Neisseria Conference, 11–16 September 2010, Banff, Canada.
13.
EngstromE., MartinsR.M., MaiaM.L.S., SepulvedaC., CamachoL.A.B., LealM.L., SilveiraI.A.F.B., HommaA., & JessourounE. (2012). Phase II clinical study of a Brazilian meningococcal C conjugate vaccine, p. 283, Proceedings of the 18th International Pathogenic Neisseria Conference, 9–14 September 2012, Würzburg, Germany.
14.
World Health Organisation (1992). Annex 1: Good manufacturing practices for pharmaceutical products, Part One. In WHO Expert Committee on Specifications for Pharmaceutical Preparations. Thirty-Second Report (WHO Technical Report Series, No. 823).Geneva, Switzerland: WHO.
MetzB., HendriksenC.F., JiskootW., & KerstenG.F. (2002). Reduction of animal use in human vaccine quality control: Opportunities and problems. Vaccine20, 2411–2430.
19.
van der PolL., StorkM., & van der LeyP. (2015). Outer membrane vesicles as platform vaccine technology. Biotechnology Journal10, 1689–1706.
20.
Anon. (2011). Meningococcal group C conjugate vaccine. In The European Pharmacopoeia, 5th Edition, Chapter 2112. Strasbourg, France: European Pharmacopoeia (Ph. Eur.) Commission.
ICCVAM (2008). Validation status of five in vitro test methods proposed for assessing potential pyrogenicity of pharmaceuticals and other products. ICCVAM Test Method Evaluation Report: Section 3.0, 10 pp. Durham, NC, USA: ICCVAM. Available at: https://ntp.niehs.nih.gov/iccvam/docs/pyrogen/tmer/3-status.pdf (Accessed 10.10.18).
28.
ICCVAM (2008). Introduction and rationale for the proposed use of in vitro pyrogen test methods. In ICCVAM In Vitro Pyrogenicity BRD, Section 1, 10 pp. Durham, NC, USA: ICCVAM. Available at: https://ntp.niehs.nih.gov/iccvam/docs/pyrogen/brd/1-intro.pdf (Accessed 25.01.18).
29.
GimenesI., CaldeiraC., MouraW.C., PresgraveO.A.F., & VillasBoas M.H.S. (2015). Assessment of pyrogenic response of lipoteichoic acid by the monocyte activation test and the rabbit pyrogen test. Regulatory Toxicology & Pharmacology73, 356–360.
30.
HasiwaN., DaneshianM., BrueggerP., FennrichS., HochadelA., HoffmannS., Rivera-MarianiF.E., RockelC., SchindlerS., SpreitzerI., StoppelkampS., VysyarajuK., & HartungT. (2013). Evidence for the detection of non-endotoxin pyrogens by the whole blood monocyte activation test. ALTEX30, 169–208.
31.
SolatiS., AardenL., ZeerlederS., & WoutersD. (2015). An improved monocyte activation test using cryopreserved poolled human mononuclear cells. Innate Immunology21, 677–684.
32.
SchindlerS., SpreitzerI., LöschnerB., HoffmannS., HennesK., HalderM., BrüggerP., FreyE., HartungT., & MontagT. (2006). International validation of pyrogen tests based on cryopreserved human primary blood cells. Journal of Immunological Methods316, 42–51.
33.
Farmacopéia brasileira (2010). Pirogênios. In Agência Nacional de Vigilância Sanitária, 5a ed. pp. 229–230, Brasília, DF, Brasil: Agência Nacional de Vigilância San itária.
HoffmannS., Rivera-MarianiF.E., RockelC., SchindlerS., SpreitzerI., StoppelkampS., VysyarajuK., & HartungT. (2013). Evidence for the detection of non-endotoxin pyrogens by the whole blood monocyte activation test. ALTEX30, 169–208.
36.
RockelC., & HartungT. (2012). Systematic review of membrane components of Gram-positive bacteria responsible as pyrogens for inducing human monocyte/ macrophage cytokine release. Frontiers in Pharmacology3, 56.
37.
GaoJ.J., XueQ., ZuvanichE.G., HaghiK.R., & MorrisonD.C. (2001). Commercial preparations of lipoteichoic acid contain endotoxin that contributes to activation of mouse macrophages in vitro.Infection & Immunity, 69, 751–757.
38.
NavegaE.C.A., SilvaC.C., PresgraveO.F., AlmeidaA.S., DelgadoI.F., & MattosK.A. (2015). Métodos alternativos ao uso de animais para a detecção de pirogênio: Oportunidades e desafios no controle da qualidade de produtos biológicos. Archives of Veterinary Science20, 71–81.
39.
SilvaC.C., OliveiraC.B.N., CarneiroP.S., MarengoE.B., MattosK.A., AlmeidaR.S.C., SpoladoreJ., AlvesG.G., PresgraveO.A.F., & DelgadoI.F. (2018). Métodos alternativos para a detecção de pirogênios em produtos e ambientes sujeitos a Vigilância Sanitária: Avanços e perspectivas no Brasil a partir do reconhecimento internacional do Teste de Ativação de Monócitos. Visa em Debate6, 137–149.
40.
Anon. (2008). EU Guidelines to Good Manufacturing Practice, Medicinal Products for Human and Veterinary Use. Annex 1: Manufacture of Sterile Medicinal Products, 16 pp. Brussels, Belgium: European Commission. Available at: http://academy.gmp-compliance.org/guidemgr/files/ANNEX%2001%5b2008%5d.PDF (Accessed 25.01.18).
41.
CusslerK., HalderM., & HendriksenC. (2002). Future activities: ECVAM and the quality control of biologicals. ATLA30, S2, 225–226.
42.
Perdomo-MoralesR., Pardo-RuizZ., SpreitzerI., LagartoA., & MontagT. (2011). Monocyte activation test (MAT) reliably detects pyrogens in parenteral formulations of human serum albumin. ALTEX28, 227–235.
43.
SilvaC.C., PresgraveO.A., HartungT., de MoraesA.M., & DelgadoI.F. (2016). Applicability of the Monocyte Activation Test (MAT) for hyperimmune sera in the routine of the quality control laboratory: Comparison with the Rabbit Pyrogen Test (RPT). Toxicology in Vitro32, 70–75.
44.
StoddardM.B., PintoV., KeiserP.B., & ZollingerW. (2010). Evaluation of a whole-blood cytokine release assay for use in measuring endotoxin activity of group B Neisseria meningitidis vaccines made from lipid A acylation mutants. Clinical & Vaccine Immunology17, 98–107.
45.
CaiT., ZhangY., HeQ., LiuQ., DuY., ChenC., & GaoH. (2017). The suitability of meningococcal groups ACYW135 polysaccharide vaccine for human peripheral blood mononuclear cell (PBMC) in vitro pyrogen test. Science & Technology Review, 35, 88–91.
46.
CarlinG., & ViitanenE. (2005). In vitro pyrogenicity of the diphtheria, tetanus and acellular pertussis components of a trivalent vaccine. Vaccine23, 3709–3715.
47.
MattosK.A., NavegaE.C.A., SilvaV.F., AlmeidaA.S., SilvaC.C., PresgraveO.A.F., Guedes JuniorD.S., & DelgadoI.F. (2018). Applicability of the Monocyte Activation Test (MAT) in the quality control of the 17DD yellow fever vaccine. ATLA46, 1–15.
48.
VipondC., FindlayL., FeaversI., & CareR. (2016). Limitations of the rabbit pyrogen test for assessing meningococcal OMV based vaccines. ALTEX33, 47–53.
49.
KoryakinaA., FreyE., & BrueggerP. (2014). Cryopreservation of human monocytes for pharmacopeial monocyte activation test. Journal of Immunological Methods405, 181–191.
50.
CartmellT., PooleS., TurnbullA.V., RothwellN.J., & LuheshiG.N. (2000). Circulating interleukin-6 mediates the febrile response to localised inflammation in rats. Journal of Physiology526, 653–661.
51.
GainesD.R.E., BruggerP., PatelM., MistryY., & PooleS. (2004). Monocyte activation test for pro-inflammatory and pyrogenic contaminants of parenteral drugs: Test design and data analysis. Journal of Immunological Methods288, 165–177.
52.
StoppelkampS., WürschumN., StangK., LöderJ., Avci-AdaliM., SchlensakL.T.C., & WendelH.P. (2017). Speeding up pyrogenicity testing: Identification of suitable cell components and readout parameters for an accelerated monocyte activation test (MAT). Drug Testing & Analysis9, 260–273.
KimH., JungB.J., KimJ.Y., & ChungD.K. (2014). Differential effects of low and high doses of lipoteichoic acid on lipopolysaccharide-induced interleukin-6 production. Inflammation Research63, 419–428.
55.
KobayashiG.S., & FriedmanL. (1964). Characterization of the pyrogenicity of Candida albicans, Saccharomyces cerevisiae, and Cryptococcus neoformans.Journal of Bacteriology, 88, 680–866.
UlanovaM., TarkowskiA., Hahn-ZoricM., & HansonL.Å. (2001). The common vaccine adjuvant aluminum hydroxide up-regulates accessory properties of human monocytes via an interleukin-4-dependent mechanism. Infection & Immunity69, 1151–1159.
58.
HeP., ZouY., & HuZ. (2015). Advances in aluminum hydroxide-based adjuvant research and its mechanism. Human Vaccines & Immunotherapeutics11, 477–488.
59.
LiH., WillinghamS.B., TingJ.P-Y., & ReF. (2008). Cutting edge: Inflammasome activation by Alum and Alum's adjuvant effect are mediated by NLRP3. Journal of Immunology181, 17–21.
60.
KaaijkP., van StraatenI., van de WaterbeemdB., BootE.P., LevelsL.M., van DijkenH.H., & van den DobbelsteenG.P. (2013). Preclinical safety and immunogenicity evaluation of a nonavalent PorA native outer membrane vesicle vaccine against serogroup B meningococcal disease. Vaccine31, 1065–1071.
61.
MartisL., PatelM., GiertychJ., MongovenJ., TaminneM., PerrierM.A., MendozaO., GoudN., CostiganA., DenjoyN., VergerC., & OwenW.F.Jr. (2005). Aseptic peritonitis due to peptidoglycan contamination of pharmacopoeia standard dialysis solution. The Lancet365, 588–594.
